Aldeyra Therapeutics (NASDAQ: ALDX) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Volatility & Risk

Aldeyra Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Aldeyra Therapeutics and bluebird bio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aldeyra Therapeutics 0 0 4 0 3.00
bluebird bio 2 6 13 0 2.52

Aldeyra Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 160.42%. bluebird bio has a consensus price target of $109.17, suggesting a potential downside of 20.52%. Given Aldeyra Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Aldeyra Therapeutics is more favorable than bluebird bio.

Insider & Institutional Ownership

49.1% of Aldeyra Therapeutics shares are owned by institutional investors. 28.4% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 3.9% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Aldeyra Therapeutics and bluebird bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aldeyra Therapeutics N/A -80.41% -70.58%
bluebird bio -1,080.59% -32.19% -25.23%

Valuation and Earnings

This table compares Aldeyra Therapeutics and bluebird bio’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Aldeyra Therapeutics N/A N/A -$19.82 million ($1.46) -4.93
bluebird bio $26.65 million 234.96 -$259.89 million ($7.36) -18.66

Aldeyra Therapeutics has higher revenue, but lower earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Aldeyra Therapeutics beats bluebird bio on 7 of the 12 factors compared between the two stocks.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

bluebird bio Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.